BlackRock Group’s Iovance Biotherapeutics IOVA Stock Holding History

BlackRock Group’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$4.8M	Buy	690,300 +1,428	+0.2%	+$9.83K	﹤0.01%	1218
2016 Q3	$5.67M	Buy	688,872 +675,700	+5,130%	+$5.72M	﹤0.01%	1068
2016 Q2	$107K	Sell	13,172 -204	-2%	-$1.28K	﹤0.01%	2775
2016 Q1	$68K	Buy	13,376 +5,522	+70%	+$30.2K	﹤0.01%	2858
2015 Q4	$60K	Sell	7,854 -272	-3%	-$1.89K	﹤0.01%	2795
2015 Q3	$47K	Sell	8,126 -20,365	-71%	-$159K	﹤0.01%	2858
2015 Q2	$262K	Buy	28,491 +11,656	+69%	+$130K	﹤0.01%	2505
2015 Q1	$204K	Buy	+16,835	New	+$190K	﹤0.01%	2492

Other funds holding IOVA

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Group's IOVA Position: Q4 2016 in Review

BlackRock Group increased its Iovance Biotherapeutics (IOVA) stake by 0.21% in Q4 2016, buying an estimated $9.83K and bringing the position to 690,300 shares worth $4.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1218.

BlackRock Group first reported a position in IOVA in Q1 2015 and has held it in 8 quarters since. The position peaked at $5.67M in Q3 2016. 87 funds tracked by Wall St. Rank hold IOVA as of Q4 2016.

BlackRock Group held 690,300 shares of Iovance Biotherapeutics worth $4.8M as of Q4 2016.
BlackRock Group bought 1,428 Iovance Biotherapeutics shares in Q4 2016, an estimated $9.83K.
Iovance Biotherapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1218 holding.
BlackRock Group first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 8 quarters since.
BlackRock Group's Iovance Biotherapeutics position peaked at $5.67M in Q3 2016.
87 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.